The O-Ag Antibody Response to Francisella Is Distinct in Rodents and Higher Animals and Can Serve as a Correlate of Protection

Lauren E. Shoudy 1,†, Prachi Namjoshi 2,†, Gabriela Giordano 1,‡, Sudeep Kumar 2, Jennifer D. Bowling 3, Carl Gelhaus 4, Eileen M. Barry 5, Allan J. Hazlett 6, Brian A. Hazlett 7,†, Kristine L. Cooper 8, Phillip R. Pittman 9, Douglas S. Reed 3,† and Karslen R. O. Hazlett 1,2,†

1 Department of Regenerative and Cancer Cell Biology, Albany Medical College, Albany, NY 12208, USA; cowenl@amc.edu (L.E.S.); gabriela_giordano@hms.harvard.edu (G.G.)
2 Department of Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA; pnamjosh@utk.edu (P.N.); KumarS@amc.edu (S.K.)
3 Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA 15261, USA; jeb263@pitt.edu (J.D.B.); dsweed@pitt.edu (D.S.R.)
4 MRI Global, Kansas, MO 64110, USA; cgelhaus@MRIGLOBAL.ORG
5 Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA; embarry@som.umaryland.edu
6 Department of Philosophy, Washington University, St Louis, MO 63130, USA; ahazlett@wustl.edu
7 Department of Ecology and Evolutionary Biology, University of Michigan, Ann Arbor, MI 48109, USA; calcushazletti@gmail.com
8 Hillman Cancer Center, Biostatistics Facility, University of Pittsburgh, Pittsburgh, PA 15261, USA; KLC183@pitt.edu
9 U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Fredrick, MD 21702, USA; phillip.r.pittman.civ@mail.mil
† Current addresses: P.N.—Department of Biomedical and Diagnostic Sciences, University of Tennessee, Knoxville, TN 37996, USA; G.G.—Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA; B.A.H.—Turkixing Institute, Ann Arbor, MI 48105, USA.

Abstract: Identifying correlates of protection (COPs) for vaccines against lethal human (Hu) pathogens, such as Francisella tularensis (Ft), is problematic, as clinical trials are currently untenable and the relevance of various animal models can be controversial. Previously, Hu trials with the live vaccine strain (LVS) demonstrated ~80% vaccine efficacy against low dose (~50 CFU) challenge; however, protection deteriorated with higher challenge doses (~2000 CFU of SchuS4) and no COPs were established. Here, we describe our efforts to develop clinically relevant, humoral COPs applicable to high-dose, aerosol challenge with S4. First, our serosurvey of LVS-vaccinated Hu and animals revealed that rabbits (Rbs), but not rodents, recapitulate the Hu O-Ag dependent Ab response to Ft. Next, we assayed Rbs immunized with distinct S4-based vaccine candidates (S4∆guaBA, S4∆clpB, and S4∆aroD) and found that, across multiple vaccines, the %O-Ag dep Ab trended with vaccine efficacy. Among S4∆guaBA-vaccinated Rbs, the %O-Ag dep Ab in pre-challenge plasma was significantly higher in survivors than in non-survivors; a cut-off of >70% O-Ag dep Ab predicted survival with high sensitivity and specificity. Finally, we found this COP in 80% of LVS-vaccinated Hu plasma samples as expected for a vaccine with 80% Hu efficacy. Collectively, the %O-Ag dep Ab response is a bona fide COP for S4∆guaBA-vaccinated Rb and holds significant promise for guiding vaccine trials with higher animals.

Keywords: Francisella; O-Antigen; animal models; rabbits; rodents; humans

1. Introduction

Tularemia (also known as rabbit fever) is a severe disease caused by Francisella tularensis (Ft), a Gram-negative, facultative intracellular bacterium [1]. While Ft can be transmitted...
by arthropods or direct contact, the most serious form of disease results from inhalation of Type A strains of the bacteria. The infectious aerosolized dose for humans (Hu) is ~15 Ft and untreated pneumonic tularemia has a 40–60% fatality rate [2]. It is unclear how Ft causes such severe mortality, although it infects many cells, including macrophages, dendritic cells, epithelial cells, and hepatocytes [3]. Lung and liver damage resulting from Ft replication and immunopathology is often fatal.

There are currently no tularemia vaccines licensed for Hu use. While disease incidence in the USA is currently low, Ft is a Tier 1 select agent due to its historical use as a bioweapon and its ease of aerosol infection; as such, it is a priority for vaccine development. The live-vaccine strain (LVS) was developed in the 1950s from Ft subsp. holarctica and used as an investigational new drug by USAMRIID until 2019, although reversion to virulence remains a concern [4]. Studies in the 1960s determined that scarification with LVS offers ~80% protection to Hu against low-dose (~50 CFU) aerosol exposure to Type A Ft Schu S4 (S4); protection deteriorated with high challenge doses (≥2000 CFU) triggering antibiotic rescue of unprotected Hu [5]. Aerosol delivery of LVS was subsequently shown to be superior to the dermal route; however, Hu protection remained ~80% [6]. No correlates of protection (COPs) were identified in these human studies.

In more recent times, we and others have postulated that live S4-based vaccines would provide better protection against type A strains. We engineered S4 vaccine candidates with unmarked deletions in genes (guaBA and aroD) encoding critical enzymes in biosynthetic pathways; similar mutations in the enteric pathogens Shigella and Salmonella Typhi resulted in promising vaccine strains that are safe, highly attenuated, and immunogenic for Hu in clinical trials [7–9]. Independently, the Conlan and Sjostedt groups developed and characterized a S4 vaccine candidate, S4ΔclpB, which lacks a chaperone protein required for secretion of virulence factors (see [10] and references therein). All three S4-based vaccine candidates (S4ΔclpB, S4ΔguaBA, and S4ΔaroD) have been tested for attenuation and vaccination efficiency (VE) in one or more rodent models (mice (Mo), guinea pigs, rats (Rt)) [10–12]. Vaccination of rodents with S4ΔaroD or S4ΔclpB each provided protection superior to LVS against S4 challenge. Interestingly, S4ΔguaBA vaccination in the Mo model did not provide protection, in stark contrast to results in the rabbit (Rb) model. In outbred Rbs, both S4ΔaroD and S4ΔguaBA provide protection (≥50% VE) superior to LVS when challenged by aerosol with high doses (~2000 CFU) of S4 [13,14]. Results from vaccine trials with S4ΔclpB in a non-rodent system are pending [10]. To date, no side-by-side comparison of these three S4-based candidates in an identical system has been reported.

Licensure of tularemia vaccines will require pivotal efficacy studies in animals because Hu efficacy trials are untenable. In such cases, the Food & Drug Administration (FDA) allows for studies to be performed in animals under the “Animal Rule” which requires that “the effect is demonstrated in more than one animal species expected to react with a response predictive for humans.” Inbred Mo are unsuitable models given their well-recognized susceptibility to attenuated Ft strains. Rats (Rt) [15–19] and “higher” outbred animals, such as Rb [20–23] and non-human primates (NHP) [15,24–28], have a more Hu-like susceptibility to Ft. However, as we show here, Mo and Rt α-Ft antibody (Ab) responses do not fulfill the animal rule because of their striking dissimilarity to Hu α-Ft Ab responses. The Animal Rule also requires characterization of the immune response in the model associated with protection. Developing minimally invasive, clinically translatable correlates of protection (COPs) (here defined as pre-challenge metrics that predict, with statistical significance, S4 challenge outcome (survival-S or non-survival-NS)) in a relevant, outbred model will allow extrapolation to predict Hu protection.

One of our goals is to identify humoral COPs applicable to high-dose, aerosol challenge with S4. Following optimization and standardization, such COPs could be used i) to guide future vaccine development choices, and/or ii) to determine which Hu-LVS vaccine recipients are truly protected vs. those that remain at risk. Here, our findings first lead us to conclude that Rbs, but not rodents, are a model appropriate to our goal. A survey of Rb Abs generated by vaccination with the three leading candidates suggests that the percentage
of vaccine-induced Ab specific for O-Ag dependent moieties (%O-Ag dep Ab) is related to vaccine efficacy. Analysis of pre-challenge Ab from vaccinated Rbs (that subsequently survived or succumb to S4 challenge) revealed that different vaccines can establish distinct COPs. For S4 ΔguaBA-vaccinated Rb, ≥70%O-Ag dep Ab is a statistically significant COP and a surrogate marker of survival. This marker was found in 80% of LVS-vaccinated Hu, as expected for a vaccine with 80% efficacy in Hu.

2. Results

2.1. O-Ag Dependent Ab Reactivity in Vaccinated Humans, Rabbits, Rats and Mice

As a foundation for our goal of identifying clinically relevant, humoral COPs, we first sought to determine which animal model most closely mimics the Hu Ab response to Ft exposure. Previously, we and others had noted that Mo and Hu plasma Ab responses to Ft LPS differ substantially [29,30]. To broaden the scope of these reports, we further evaluated the LPS-seroreactivity of Hu, Rb, Rt, and Mo primed with LVS ~30d prior to plasma collection. Plasma pools were used to simultaneously probe lysates of wildtype (WT) and wbtA (deficient for O-Ag, the sugar polymer in LPS) Ft LYS by Western blot. This approach reveals Abs that bind directly to O-Ag moieties (O-Ag specific Ab), and potentially, Ab that bind epitopes of outer membrane (OM) proteins whose conformation is O-Ag dependent. For each plasma, densitometric analysis of the WT and wbtA lanes were used to calculate the percentage of plasma Ab dependent on O-Ag. As shown in Figure 1a, Hu and Rb plasmas both revealed profound differences between the WT and wbtA lysates. By densitometry, we calculated that ~25% of the total Ab bound by WT lysates was also bound by the wbtA lysates, such that ~75% of the total plasma Ab was O-Ag dependent (Figure 1b). In contrast, with rodent plasmas (Rt, Mo), the WT vs. wbtA differences were minimal and the %O-Ag dep Ab were ~25% (Figure 1a,b).

![Figure 1. O-Ag dependent Ab reactivity in vaccinated Hu, Rb, Rt, and Mo.](image-url)

(a) Sera pooled from LVS-primed Hu (n = 10), Rb (n = 5), Rt (n = 5), and C57/B6 Mo (n = 5) were used to probe WT and wbtA LVS. “-” indicates no Ab control; the visible band is the biotinylated Ft protein AccB detected, even in the absence of Ft-specific Ab, by the streptavidin-HRP conjugate. Total protein staining of WT and wbtA lysates transferred to nitrocellulose membranes is shown in Figure S1.

(b) O-Ag dep Ab (means and standard deviations) derived from ≥3 technical repeats (circles) for each of the 13-independent pools of sera/plasma. Each of the 11 rodent pools (black bars) were derived from animals (n = 5–10) primed with LVS, unless otherwise indicated. From the left, the order of the bars are: Hu-LVS (white bar), Rb-LVS (grey bar), Rt-LVS, Rt-S4ΔclpB, C57/B6 (B6)-LVS, B6-LVS, B6-3 × LVS (prime-boost-boost), B6-3 × LVS followed by 3 × S4, B6-LVS, B6-LVSΔsodB, Swiss Webster (SW)-LVSΔsodB, Balb/c (Bc)-LVS, Bc-3 × LVS.
Similar results were obtained with nine additional rodent plasma pools, including multiple (i) genotypes (inbred: Balb/c Mo, C57BL/6 Mo, Fischer 344 Rt; outbred Swiss-Webster Mo), (ii) vaccine strains (LVS, S4ΔcLPB, LVSΔsodB), and (iii) inoculation regimens (prime, prime-boost-boost (3×), or 3× followed by 3 S4 challenges) (Figure 1b). Collectively, these results indicate that (a) the Rb model closely mimics the Hu α-O-Ag antibody response to F1 whereas rodent models do not, and (b) that “%O-Ag dep Ab” is a metric worthy of further analysis.

2.2. O-Ag Dep Ab Reactivity in Rabbits Vaccinated with S4ΔcLPB, S4ΔguaBA, or S4ΔaroD

Having failed to identify any rodent system that recapitulated the Hu Ab response to F1 vaccination (dominated by O-Ag dep Abs), we concluded that Rb were a more appropriate model for identifying Hu-relevant serological COPs. Next, we used this model to determine the %O-Ag dep Ab generated by live-attenuated vaccine candidates with differing vaccine efficacies. For these efforts, Rbs were primed and boosted prior to plasma collection and subsequent aerosol challenge with high doses of BHI-grown S4. Previously, we used this schedule in Rb to demonstrate the vaccine efficacy of LVS (20%), S4ΔguaBA (50%), and S4ΔaroD (66%) [13,14]. These existing plasmas, along with recent plasmas from S4ΔcLPB-ΔguaBA, as well as additional S4ΔguaBA-ΔaroD-vaccinated Rbs were used to probe WT and wbtA LVS by Western blot. Initially we present data with plasmas pooled by vaccine type and survival outcome (Figures 2c and 3), and finally plasmas from individual surviving and non-surviving Rbs (Figure 4, Table 1).

![Figure 2. %O-Ag dep Ab and S4-challenge survival among vaccinated Rbs. (a) Pooled plasma, drawn pre-challenge (d42) from 5 LVS-, 6 S4ΔcLPB-, 6 S4ΔguaBA-, and 12 S4ΔaroD-primed (d0) and boosted (d14) Rbs, were used to probe lysates of WT and wbtA F1 LVS. Total, and specific, protein detection in WT and wbtA lysates is shown in Figure S2 (b) Cumulative survival among 69 vaccinated and control Rbs challenged by aerosol with BHI-grown S4 (d44). S4 challenge (d44) doses were ~500 CFU for LVS trials and ~2000 CFU for S4-based vaccines. Portions of the survival data have been reported for Mock (n = 8)-, LVS (n = 5)-, S4ΔguaBA (n = 6)-, and S4ΔaroD (n = 12)-vaccinated Rbs and are provided here in combination with recent results from Mock (n = 8)-, S4ΔguaBA (n = 6)-, S4ΔaroD (n = 18)-, and S4ΔcLPB (n = 6)-vaccinated Rbs. Log-rank tests were adjusted for multiple comparisons; p values reflect comparisons with LVS. (c) Pre-challenge plasma from S4ΔguaBA- and S4ΔaroD-vaccinated Rbs were pooled by vaccine type from S and NS and used to probe lysates of WT and wbtA F1 LVS.](image-url)
Figure 3. Blotting of *Ft* fractions with survivor and non-survivor plasmas reveals multiple putative humoral COPs. *Ft* grown in MHB (M) or BHI (B) were fractionated into Aq, D, SS, and SI phases prior to Western blot analysis with plasma banked from S4ΔaroD—(a,b) or S4ΔguaBA—(c,d) vaccinated Rb. Following S4 challenge completion, S and NS pools were generated from the banked plasmas. Arrows: putative proteins differentially recognized by S and NS Ab. Brackets: O-Ag rich moieties (LPS—SI phase; capsular O-Ag—D-phase) differentially recognized by S4ΔguaBA S and NS Ab. See Figure S3 for total protein staining of SDS-PAGE resolved Aq, D, SS, and SI phases.

Figure 4. %O-Ag dep Ab in NS and S S4ΔguaBA-vaccinated Rbs. Individual Rb sera were used to probe WT and *wbtA* LVS. Mean %O-Ag dep Ab were derived from >3 repeats. Detection of IgIB, IgIC, and Tul4 is shown in Figure S4.
Table 1. %O-Ag dep Ab is a COP for S4guaBA-vaccinated Rbs.

|         | NS          | S          |
|---------|-------------|------------|
| Range   | 43–70%      | 68–81%     |
| Mean    | 60%         | 76%        |
| WRS     |             |            |
| p       | 0.009       |            |
| ROC AUC | 0.94, 95% CI (0.82, 1.00) | 70% cut-off = 83% Sensitivity, Specificity. |

For Rb vaccinated with LVS, the %O-Ag dep Ab was not markedly different between animals that received a single inoculation and those that were boosted, 72% and 80% respectively (Figures 1 and 2). Among the S4-based vaccines, the %O-Ag dep Ab ranged from 52% (S4ΔclpB), to 63% (S4guaBA), to 74% (S4aroD). Interestingly, both the S4ΔclpB- and S4guaBA-induced Ab reacted with a very low MW, O-Ag independent species (Figure 2a, box) that was unreactive with LVS- and S4aroD-induced Ab. When the %O-Ag dep Ab values were considered in light of our long-term cumulative survival data (Figure 2b), we noted a trend in which the vaccine efficacy of the S4-based candidates trended with the %O-Ag dep Ab induced by the vaccination. Specifically, vaccination with S4ΔclpB induced 52%O-Ag dep Ab and provided 33% protection, vaccination with S4guaBA induced 63%O-Ag dep Ab and provided 50% protection, S4aroD vaccination induced 74%O-Ag dep Ab and provided 73% protection. These observations suggest that %O-Ag dep Ab in higher animals might be a general predictor of vaccine function among S4-based candidates. We next sought to determine if %O-Ag dep Ab could predict survival within a single vaccination group. The ≥50% vaccine efficacy in S4guaBA- and S4aroD-immunized Rb provided sufficient survivors (S) and non-survivors (NS) to generate plasma pools comprised exclusively of S or NS for each vaccine group. For the S4aroD plasma, the %O-Ag dep Ab did not differ between S and NS (70% vs. 68%, Figure 2c). In contrast, the values in S4guaBA S plasma (70%) were higher that of the S4guaBA NS plasma (58%).

With these plasmas, we noted several O-Ag independent bands (presumably proteins) of reactivity within each vaccine type that were restricted to either the S or NS pools (Figure 2c). To delve more deeply into the Ft Ags differentially recognized by NS or S plasma, we fractionated WT LVS (grown in either MHB or BHI to broaden the Ag repertoire) into Tx114 aqueous (Aq) and detergent (D) phases while the Tx-insoluble material was fractioned further into sarkosyl-soluble (SS) and sarkosyl-insoluble (SI) components. This approach partitions the O-Ag rich moieties—high MW capsular O-Ag and LPS—into the D and SI phases, respectively, thereby allowing detection of additional Ags [31,32]. We observed that most dominant protein Ags were commonly recognized by S and NS plasma from S4aroD and S4guaBA (Figure 3); however, close examination revealed several Ags that were differentially recognized by S and NS Ab (Figure 3, arrows). Several of these Ags were recognized commonly by S4aroD and S4guaBA, while others appeared unique to a single vaccine type. Characterization of these protein species will be described elsewhere.

Among the O-Ag rich moieties—capsular O-Ag (in the D phases) and LPS (in the SI phases)—we did not observe differences between S and NS Ab in the S4aroD plasmas (Figure 3a,b). However, the S4guaBA survivor and non-survivor Abs revealed striking differences in recognition of O-Ag capsular material and LPS (Figure 3c,d, brackets). A low MW species (potentially un-glycosylated lipid A) recognized exclusively by survivor S4guaBA plasma was observed primarily in the D phase of MHB-grown Ft (Figure 3c bottom arrows). These findings, based on WT (non-mutant) Ft, also indicate that elevated α-O-Ag Ab levels are a characteristic of survival in S4guaBA-vaccinated Rbs.

2.3. O-Ag Dep Ab Is a Correlate of Protection in S4guaBA-Vaccinated Rabbits

Next, we determined the %O-Ag dep Ab for plasmas from individual S4guaBA-vaccinated Rb; an example is shown in Figure 4 (also see Figure S4 in the Supplementary Materials). When multiple NS (n = 6) and S (n = 6) S4guaBA plasma were assayed, the average %O-Ag dep Ab values were 60% for NS and 76% for S. These differences
were significant by the Wilcoxon Rank Sum test (WRS, \( p = 0.014 \)). The anti-\( \alpha \)-\( Ft \) ELISA-determined titers for the S (1575 ± 950) and the NS (1994 ± 1213) were not significantly different. Receiver operating characteristic (ROC) analysis is used to evaluate the utility of a measurement for predicting an outcome. ROC analysis of %O-Ag dep Ab as a classification model for survival yielded an AUC = 0.94, 95% CI (0.82, 1.00). A cut-off of 70% yields 83% sensitivity and 83% specificity for predicting challenge survival. Thus, an elevated (>70) %O-Ag dep Ab is a statistically significant COP for S4\( \Delta \)guaBA-vaccinated Rbs.

2.4. O-Ag Dep Ab in LVS-Vaccinated Humans

As our Rb data suggests that >70 %O-Ag dep Ab is a COP, we sought to determine if this metric had relevance to Hu. Currently there are no plasma from S4\( \Delta \)guaBA-vaccinated Hu. There are, however, (i) banks of plasma from LVS-vaccinated Hu, and (ii) data indicating that LVS vaccination of Hu is ~80% effective in preventing disease induced by low doses (~50 CFU) of S4 [5,6]. Based on the rationale that \textit{bona fide} COPs should therefore be present in ~80% of LVS-vaccinated Hu plasma, we assessed Hu plasma drawn from 10 LVS-vaccine recipients ~d30 post-vaccination. The %O-Ag dep Ab among the Hu ranged from 66–88% (Figure 5) with a mean of 79%. Only two of these plasmas (#4 and #8) had O-Ag dep Ab values below 70%. The remaining 80% had higher values, reminiscent of S4\( \Delta \)guaBA-vaccinated Rbs that went on to survive S4 challenge. It is worth noting that %O-Ag dep Ab is not predicted by simple \( \alpha \)-\( Ft \) ELISA titer analysis. The Hu plasma having the highest titers (1280 and 2560) did not stand out in the %O-Ag dep Ab assays. Similarly, plasma (#4 and 8) had the same titers (320–640) as many other plasma (#2, 3, 7, and 9) that did not stand out. Thus, this COP, developed using S/NS Rbs and present in vaccinated Hu, appears to be a novel metric providing distinct information that augments and/or surpasses anti-\( Ft \) Ab titer data obtained by ELISA.

![Figure 5. %O-Ag dep Ab in LVS-vaccinated Hu.](image)

3. Discussion

Defining COPs for rare infectious diseases is not trivial, as establishing protection involves willingly infecting humans; in the case of highly lethal pathogens this is not possible in modern times. In the Cold War era, protection afforded by immunization with LVS was determined by challenging vaccinated Hu with aerosols of S4 and monitoring for overt clinical disease (a lack of protection which cued antibiotic intervention) [2,5,6]. Collectively, these Hu studies quantified LVS-mediated protection against low dose S4 challenge as ~80%. However, despite the efforts of multiple groups, no COPs were identified, such that 20% of Hu LVS vaccinees remain unprotected and unidentified. Moreover, the lack of Hu COPs has continued to hinder development of novel tularemia vaccine candidates.

To circumvent the limitations of Hu-based research, animals have been used as surrogates in efforts to identify COPs, both cellular [33–42] and humoral [33,36,43,44].
Most frequently, these efforts have involved immunizing rodents with vaccine candidates that provide varying degrees of protection and then analyzing induced responses (cells, cytokines, antibodies, etc.) of the differentially immunized groups. We similarly sought to ID clinically-useful, serological COPs but planned to bank individual vaccine-induced Ab samples for retrospective analysis after each animal’s S4 challenge outcome—survival or non-survival—was known. As a foundation for these studies, we compared the serum Ab responses of LVS-vaccinated mice, rats, and Rbs, to that of humans to inform our choice of animal model. By simultaneously assessing the reactivity of Ab samples with O-Ag sufficient and deficient Ft, we were able to determine the percentage of vaccine-induced Ab response that was dependent on O-Ag. This internally controlled approach allows for the comparison between plasma/sera of different titers and across species. While differences between Mo and Hu α-LPS responses have been reported [29,30], the results here from side-by-side quantification of rodent, Rb, and Hu α-O-Ag Ab responses to LVS immunization were none-the-less, quite striking. Hu and Rb responses were dominated by O-Ag-dep Ab (~75% of the total Ft-specific Ab), whereas in rodents the same measure was ~25%. Multiple attempts to increase this value in rodents included (i) varying the strain of inbred rodent, (ii) the use of outbred rodents, (iii) alteration of the vaccine regimen/route, and (iv) the use of distinct vaccine candidates. Collectively, our data suggest a fundamental discord between rodents and higher animals regarding the O-Ag dep Ab responses to Ft infection. In this regard, our findings are conceptually very similar to those of Rahhal et al., in which Hu B cells were found to be significantly more responsive than Mo B cells to purified Ft LPS [45]. Our data do not mean that rodents fail to produce α-LPS Ab following Ft infection, just that they do so to a much lesser extent—with a greater focus on protein Ags—than higher animals such as Rb and Hu.

The mechanism(s) underlying this difference is unknown to us, as is the extent to which this difference may also apply to other Gram-negative infections. All the rodents in our study were purchased and maintained under SPF (specific pathogen free) conditions and such abnormally hygienic conditions impact development of the immune system [46]. The Rbs in our studies were also purchased and maintained under SPF conditions, although the qualifications for SPF rodents and SPF Rbs are not identical. Thus, while differences in the “cleanliness” of SPF-rodents, SPF-Rbs, and adult Hu likely contribute to our findings, other factors such as germ line, genotypic differences [47] cannot be excluded.

Operationally, regardless of the mechanism(s), these findings revealed that Rbs were the animal of choice in which to search for Hu-relevant, serological COPs. When rabbits were immunized with different strains, we found that vaccine-induced %O-Ag dep Ab (52–74%) trended with the vaccine efficacy (33–73% respectively) for S4-based strains. However, vaccination with LVS was poorly protective (20%) despite yielding a high %O-Ag dep Ab (80%). To account for the above results, we envisioned two possible explanations: (i) %O-Ag dep Ab can act as a COP only when combined with another type/facet of immunity (preferentially provided by S4-based vaccines), or (ii) %O-Ag dep Ab is a correlate for some, but not all, S4-based Ft vaccines. To discern these possibilities, we characterized responses of survivors and non-survivors emanating from immunization with two vaccine strains (S4ΔaroD and S4ΔguaBA) that provided ≥50% protection. Collectively, the antigenic differences between S4ΔaroD-vaccinated S and NS appeared to involve a small set of protein Ags (Figure 3), but no discriminatory involvement of O-Ag moieties (both S4ΔaroD S and NS have ~70% O-Ag dep Ab). In contrast, S4ΔguaBA-vaccinated S and NS were strongly differentiated by %O-Ag dep Ab, with lesser discrimination by protein Ags. Thus, it appears that the protective immunity provided by S4ΔaroD is mechanistically different than the protective immunity provided by S4ΔguaBA. The low survival rate among LVS- and S4ΔclpB-vaccinated Rb challenged with high doses of S4 precluded characterization of the infrequent protective immunity/COPs for these strains. The notion that different vaccines targeting a single infectious agent could have distinct mechanisms of protection and distinct COPs is well-established [48].
While the goal of this work was to identify correlates of protection, and correlation does not mean causation, we can envision a mechanism by which high %O-Ag dep Ab could reflect effector functions that contribute to the survival of $S4_{\Delta\text{guaBA}}$-vaccinated Rbs challenged with $S4$. While unopsonized $Ft$ replicate exponentially in host MΦs, $Ft$ opsonized with saturating concentrations of complement or α-LPS Ab gain cellular entry through phagocytic receptors (complement- and/or Fc-receptors) and show limited intracellular replication [49]. Thus, in vaccinated higher animals (which are capable of mounting a robust α-OAg Ab response), a sufficiently O-Ag-focused Ab response would lead to opsonization of an $S4$ challenge bolus with Ab (and classically-activated C'). The resulting restricted intracellular replication could allow time for additional vaccine-induced effectors (cytokines, cell-mediated immunity, etc.) to engage. In this scenario; %O-Ag dep Ab could be considered either a mechanistic COP or potentially, a co-correlate [48]. Opsonophagocytosis assays with Rb S and NS sera are underway to determine the impact of these sera on intracellular growth of $Ft$. In the context of $S4_{\Delta\text{guaBA}}$-vaccinated animals, our Rb sera fits nicely in the above rationale, as S had significantly higher %O-Ag dep Ab than NS, such that >70%O-Ag dep Ab is a statistically significant indicator of survival. Moreover, this notion also fits with our findings that vaccination of mice (which mount limited α-LPS Ab responses) with $S4_{\Delta\text{aroD}}$ is not protective [12]. While the above scenarios describe a positive correlate/activity that is preferentially present in the survivor samples, it is also theoretically possible that a negative correlate/detrimental activity is overly abundant in the NS samples. Both the $S4_{\Delta\text{guaBA}}$ and $S4_{\Delta\text{aroD}}$ NS sera samples displayed Ab reactivities with proteins that were non-reactive with the corresponding S sera (Figures 2–4). Identification of these $Ft$ proteins is in progress.

Formally proving that a candidate COP (such as %OAg-dep Ab, or Ab reactivity with specific $Ft$ protein Ags) is Hu-relevant is daunting, as Hu-vaccination and challenge studies ended in the 1960s. However, sampling individual vaccine-induced Hu responses (when the level of vaccine-mediated protection is known) can exclude candidate responses as COPs if their frequency is markedly different from the known frequency of protection. In other words, a true Hu-relevant COP should be present in ~80% of the Hu LVS vaccinee population. Responses that are present in 20% (or 100%) of the Hu LVS vaccinee population are likely not true COPs. In this light, we surveyed a small set of Hu LVS vaccinee sera for the Rb-derived COP “≥70%O-Ag dep Ab”. Our observation, that 80% of Hu had this COP, while 20% did not, indicates that this marker is a putative Hu-relevant COP and is worthy of further analysis. We have arranged for a larger sample size of Hu LVS sera for such analysis; however, definitive proof of these COPs as primate-relevant will require non-human primate (NHP) vaccination and challenge studies along the line of our Rb studies. Given the high protection rates of $S4_{\Delta\text{aroD}}$ and $S4_{\Delta\text{guaBA}}$ in Rbs (50 and 73% respectively), we envision that NHP studies with these strains would both advance tularemia vaccines and further test the notion that Rb-derived COPs have clinical utility.

4. Materials and Methods

4.1. Bacteria

The LVS strain of $Ft$ was acquired from BEI (NR-646) and was grown in vitro in MHB or BHI as previously described [31,32]. The LVS $\text{wbtA}$ mutant similarly used here has been described [50]. The $\text{clpB}$ mutant of $S4$ [10] was provided by the National Research Council-Canada. The RML isolate of LVS was provided by Catharine Bosio. Plasmid-modification of $Ft$ was by electroporation [51]. WT $Ft$ $S4$ was used within the CDC-certified A/BSL-3 facilities of Albany Medical College or the University of Pittsburgh.

Late-log phase $Ft$ grown in MHB or BHI were harvested by centrifugation ($8000 \times g$, 15 min, 20 °C). Bacterial pellets were resuspended in the appropriate fresh growth media, transferred to pre-weighed Eppendorf tubes, pelleted as above after which the transfer supernatant was aspirated. Pellet wet weights were determined and used to estimate cell numbers based upon the estimate of 1 mg of wet weight = $5 \times 10^8$ bacteria. Cells were resuspended to $5 \times 10^7 / \mu\text{L}$ in 20 mM Tris, pH 8.0 containing 100 mM NaCl, 20 μL/mL.
protease inhibitor cocktail #P8849 (Sigma, St Louis, MO, USA). These whole cell (WC) preparations were either used for SDS PAGE and western blot analysis (below) or first fractionated into Aq, D, SS, and SI phases as previously described [29].

4.2. SDS-PAGE and Western Blot Analysis

Samples derived from 10 µg of Ft protein (~1 × 10⁸ cells) were mixed with Laemmli sample buffer and boiled for 10 min prior to resolution through 4–12% gradient SDS-PAGE pre-cast gels (Invitrogen, Waltham, MA, USA). The running buffer was NuPAGE MES SD buffer from Invitrogen; gels were variously run at 90–160 V. Resolved gels were stained with either Coomassie blue (BioRad, Hercules, CA, USA) or transferred to nitrocellulose membranes. Coomassie-stained gels were scanned into Adobe Photoshop using an HP 2820 scanner. Membranes were blocked for 30 min with PBS, 0.05% Tween 20, 5% non-fat dry milk. Primary Abs were applied for overnight incubation at dilutions ranging from 1:1000 to 1:5000. The secondary Ab was a biotinylated goat α-species-specific Ab (1:1000 to 1:5000) followed by a tertiary conjugate of streptavidin-linked HRP (1:1000 to 1:5000). Development of the chemiluminescent substrate (SuperSignal West Pico and Femto, Pierce, Rockford, IL, USA) was visualized using a BioRad ChemiDoc Touch imaging system in movie mode. Densitometric analysis of developed blots was performed on the same system. Antibodies specific for the Ft proteins IglC, IglC, FopA, and Tul4 have been described previously [32].

For blots in Figures 1, 2, 4 and 5: multiple, alternating lanes were loaded with whole cell lysates of WT and wbtA LVS, resolved by SDS-PAGE and transferred to a nitrocellulose membrane. Sections of the membrane, each containing one lane of LVS and one lane of wbtA, were probed with one of the indicated plasma or sera. Except for differences in the primary antibody and species-specific secondary Ab, all membrane sections within each figure were developed under identical conditions.

4.3. Densitometric Determination of %O-Ag Dep Ab

Densitometric analysis of developed blots was performed on BioRad Image Lab 6.0 Software (BioRad, Hercules, CA, USA) in which auto exposed chemiluminescent images were analyzed via the volume tool. A large rectangle was drawn to encompass 80% of a lane and then duplicated across all lanes and top aligned. Each blot contained a “no-sera control (nsc)” lane in which WT Ft lysate was probed with only SA-HRP, or 2° Ab (biotinylated goat IgG anti-species) and SA-HRP. After outlining each lane, the volume table was exported into excel for analysis. The volume generated from the “no-sera control” lane was subtracted from the volumes of the other lanes. For each sera, a volume was calculated for each WT lysate and wbtA lysate. %O-Ag dep Ab = 100 − [Vol(wbtA − nsc)/Vol(WT-nsc) × 100]. Each sera sample was analyzed by at least three independent Western blots.

4.4. Sera/Plasma

With three exceptions detailed below (Rt α-LVS, Rt α-S4ΔclpB, and Rb α-S4ΔclpB), the generation/provision of all sera has been previously described. Mice: 2 groups of LVS primed C57BL/6 [51]; BalbC 1 ×, 3 ×; B6 3 × and 3 × LVS/3 × S4 [29]; LVSΔsodB vaccinated C57BL/6 and Swiss Webster [34]. Rabbits: LVS [13], S4ΔaroD and S4ΔguaBA [14]. Humans: [29]. Rat LVS and S4ΔclpB antisera: All rat studies were approved by MRIGlobal’s Institutional Animal Care and Use Committee (AUS 16–33) and by the U.S. Army Medical Research and Material Command’s Animal Care and Use Review Office. Fischer (CDF) 344/SuCrl (strain code 002) rats (equal mix male and female) were obtained from Charles River Laboratories (Wilmington, MA). LVS used for rat vaccinations was manufactured by the Dynport Vaccine Company and was diluted to a concentration of 2 × 10⁶ colony forming units (cfu)/mL in phosphate buffered saline (PBS). S4ΔclpB was prepared at National Research Council-Canada shipped to MRI Global. S4ΔclpB was diluted to a concentration of 2 × 10⁶ cfu/mL in PBS. Rats were shaved on the right flank and 50 µL of vaccine was injected to administer a target dose of 1 × 10⁵ cfu/rat. Blood was collected from the jugular
vein or cranial vena cava 25 days after vaccination. Blood was processed to serum and transferred to Albany Medical College for analysis. Rb S4ΔclpB antisera: Young female SPF New Zealand White Rbs (Robinson Services, Inc., Malden, MA, USA) were housed in the University of Pittsburgh Regional Biocontainment Laboratory (RBL) at ABSL-3. All studies were approved by the University of Pittsburgh’s Institutional Animal Care and Use Committee (Protocol # 19014420). Rb were primed (d0) and boosted (d14) with BHI-grown S4ΔclpB delivered by aerosol using a Collison 3-jet nebulizer and aerosol sampling with an all-glass impinger, as previously described for vaccination with BHI-grown S4AaroD and S4AguaRA [14]. Aerosol exposures were performed inside a class III biological safety cabinet in a dedicated Aerobiology suite in the University of Pittsburgh Regional Biocontainment Laboratory and controlled by a Aero3G aerosol exposure system (Biaera Technologies, Hagerstown, MD). Delivered doses of S4ΔclpB were confirmed by plate-counting as 1.4 × 10^8 CFU (prime) and 1.0 × 10^8 CFU (boost). Rb α-S4ΔclpB sera used in this manuscript were drawn on day 42 (28 post-boost). Boosted Rb were challenged by aerosol on d44 with 2.1 × 10^3 CFU of BHI-grown S4 and monitored twice daily for 28 d (until d72).

4.5. Statistics
Statistically significant differences were calculated by either GraphPad Prism 5 or Microsoft Excel. Differences in O-Ag dep Ab were determined by two-way ANOVA or t-test. p-values < 0.05 were considered significant. Percent O-Ag dependence are presented as the means and standard deviations. Rb survival: Time-to-event data was analyzed using standard survival techniques with days until sacrifice as the primary endpoint. Subjects were censored at the last day of follow up (Day 28). Technical replicates from assays were averaged within individual and two-sided non-parametric tests were used. A significance level of 0.05 was used for all analyses and p-values were adjusted for multiple comparisons (Benjamini-Hochberg method) for post-hoc tests across multiple groups. Receiver operating characteristic (ROC) curves were used to determine cut-off values for predicting survival. All analyses were performed using Rstudio (copyright 2009–2021) Version 1.4.1106 (RStudio Software company, Boston, MA, USA).

Supplementary Materials: The following are available online https://www.mdpi.com/article/10.3390/pathogens10121646/s1. Figure S1. Amido black total protein staining of WT and wbtA lysates transferred to nitrocellulose membranes; Figure S2. Detection of total and specific proteins in WT and wbtA LVS; Figure S3. Ft grown in MHB (M) or BHI (B) were fractionated into Aq, D, SS, and SI phases prior to resolution by SDS-PAGE and total protein staining with SYPRO Ruby Protein Gel Stain; Figure S4. Detection of IglB, IglC, and Tul4 in WT and wbtA LVS using a cocktail of 3 mAbs specific for these Ft proteins; Figure S5. Amido black total protein staining of WT and wbtA lysates transferred to a nitrocellulose membrane prior to being cut into discrete sections for subsequent incubation with sera/plasma.

Author Contributions: Conceptualization and design: K.R.O.H. Performed the experiments: L.E.S., P.N., G.G., J.D.B. Analyzed the data: K.R.O.H., L.E.S. Contributed to reagents/materials/analysis tools: S.K., C.G., P.R.P., D.S.R., E.M.B., A.J.H., B.A.H., K.L.C. Wrote the manuscript: L.E.S., K.R.O.H. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by grants from the National Institutes of Health (RO1AI123129—KROH, DR, EB), the Department of Defense (W81XWH1910661—KROH, HDTRA1-16-C-0028—HCC). The funding agencies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Department of Defense.

Institutional Review Board Statement: Rab studies involving S4ΔclpB were approved by the University of Pittsburgh Institutional Animal Care and Use Committee (Protocol # 19014420). Rat studies involving LVS and S4ΔclpB were approved by the IACUC at MRI Global Institutional (AUS 16-33). The use of archival, de-identified Hu sera (provided by USAMRIID) was deemed human research exempt by the Albany Medical College Institutional Review Board. Principal Investigator: Karsten
Hazlett, PhD. Title of Research Protocol: Criteria-Directed Vaccine Generation Via Ag Mimicry, Adjuvancy, And APC Targeting (Exemption 4, de-identified residual specimens) (3838).

**Informed Consent Statement:** Informed consent was obtained by USAMRIID from all subjects involved in the study.

**Data Availability Statement:** All pertinent results are contained within the article or supplement.

**Acknowledgments:** We gratefully acknowledge Wayne Conlan and the National Research Council-Canada for providing S4ΔclpB. We appreciate the constructive manuscript analysis of James Drake and Wayne Conlan.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

**References**

1. Dennis, D.T.; Inglesby, T.V.; Henderson, D.A.; Bartlett, J.G.; Ascher, M.S.; Eitzen, E.; Fine, A.D.; Friedlander, A.M.; Hauer, J.; Layton, M.; et al. Tularemia as a biological weapon: Medical and public health management. *JAMA* 2001, 285, 2763–2773. [CrossRef]

2. McCrumb, F.R. Aerosal infection of man with *Pasteurella tularensis*. *Bacteriol. Rev.* 1961, 25, 262–267. [CrossRef]

3. Meibom, K.L.; Charbit, A. The unraveling panoply of *Francisella tularensis* virulence attributes. *Curr. Opin. Microbiol.* 2010, 13, 11–17. [CrossRef]

4. Oyston, P.C.; Griffiths, R. Francisella virulence: Significant advances, ongoing challenges and unmet needs. *Expert. Rev. Vaccines* 2009, 8, 1575–1585. [CrossRef]

5. Saslaw, S.; Eigelsbach, H.T.; Prior, J.A.; Wilson, H.E.; Carhart, S. Tularemia vaccine study. II. Respiratory challenge. *Arch. Intern. Med.* 1961, 107, 702–714. [CrossRef]

6. Hornick, R.B.; Eigelsbach, H.T. Aerogenic immunization of man with live Tularemia vaccine. *Bacteriol. Rev.* 1966, 30, 532–538. [CrossRef]

7. Kotloff, K.L.; Pasetti, M.F.; Barry, E.M.; Nataro, J.P.; Wasserman, S.S.; Sztein, M.B.; Picking, W.D.; Levine, M.M. Deletion in the *guaA* and *guaB* genes further attenuates *Shigella flexneri* 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208. *J. Infect. Dis.* 2004, 190, 1745–1754. [CrossRef]

8. Kotloff, K.L.; Simon, J.K.; Pasetti, M.F.; Sztein, M.B.; Wooden, S.L.; Livio, S.; Nataro, J.P.; Blackwelder, W.C.; Barry, E.M.; Picking, W.; et al. Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media. *Hum. Vaccines* 2007, 3, 268–275. [CrossRef]

9. Tacket, C.O.; Sztein, M.B.; Losonsky, G.A.; Wasserman, S.S.; Nataro, J.P.; Edelman, R.; Pickard, D.; Dougan, G.; Chatfield, S.N.; Levine, M.M. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. *Infect. Immun.* 1997, 65, 452–456. [CrossRef]

10. Conlan, J.W.; Sjostedt, A.; Gelhaus, H.C.; Fleming, P.; McRae, K.; Cobb, R.R.; De Pascalis, R.; Elkins, K.L. Modern Development and Production of a New Live Attenuated Bacterial Vaccine, SCHU S4 DeltaclpB, to Prevent Tularemia. *Pathogens* 2021, 10, 795. [CrossRef]

11. Cunningham, A.L.; Mann, B.J.; Qin, A.; Santiago, A.E.; Grassel, C.; Lipsky, M.; Vogel, S.N.; Barry, E.M. Characterization of Schu S4 aro mutants as live attenuated tularemia vaccine candidates. *Virulence* 2020, 11, 283–294. [CrossRef]

12. Santiago, A.E.; Cole, L.E.; Franco, A.; Vogel, S.N.; Levine, M.M.; Barry, E.M. Characterization of a New Live Attenuated Bacterial Vaccine, SCHU S4 DeltaclpB, to Prevent Tularemia. *Pathogens* 2020, 9, 107. [CrossRef]

13. Layton, M.; et al. Tularemia as a biological weapon: Medical and public health management. *JAMA* 2001, 285, 2763–2773. [CrossRef]

14. O’Malley, K.J.; Bowing, J.D.; Barry, E.M.; Hazlett, K.R.O.; Reed, D.S. Development, Characterization, and Standardization of a Nose-Only Inhalation Exposure System for Exposure of Rabbits to Small-Particle Aerosols Containing Francisella tularensis. *Infect. Immun.* 2019, 87, e00198-19. [CrossRef]

15. Layton, M.; et al. Tularemia as a biological weapon: Medical and public health management. *JAMA* 2001, 285, 2763–2773. [CrossRef]

16. O’Malley, K.J.; Bowing, J.D.; Stinson, E.; Cole, K.S.; Mann, B.J.; Namjoshi, P.; Hazlett, K.R.O.; Barry, E.M.; Reed, D.S. Aerosol prime-boost vaccination provides strong protection in outbred rabbits against virulent type A Francisella tularensis. *PLoS ONE* 2018, 13, e0205928. [CrossRef]

17. Kostiala, A.A.; McGregor, D.D.; Logie, P.S. Tularemia in the rat. I. The cellular basis on host resistance to infection. *Immunology* 1975, 28, 855–869. [CrossRef]

18. Layton, M.; et al. Tularemia as a biological weapon: Medical and public health management. *JAMA* 2001, 285, 2763–2773. [CrossRef]
19. Wu, T.H.; Zsemlye, J.L.; Statom, G.L.; Hutt, J.A.; Schrader, R.M.; Scrymgeour, A.A.; Lyons, C.R. Vaccination of Fischer 344 rats against pulmonary infections by Francisella tularensis type A strains. *Vaccine* 2009, 27, 4684–4693. [CrossRef]

20. Baskerville, A.; Hambleton, P. Pathogenesis and pathology of respiratory tularemia in the rabbit. *Br. J. Exp. Pathol.* 1976, 57, 339–347.

21. Pasetti, M.F.; Cuberos, L.; Horn, T.L.; Shearer, J.D.; Matthews, S.J.; House, R.V.; Szein, M.B. An improved Francisella tularensis live vaccine strain (LVS) is well tolerated and highly immunogenic when administered to rabbits in escalating doses using various immunization routes. *Vaccine* 2008, 26, 1773–1785. [CrossRef]

22. Reed, D.S.; Smith, L.K.P.; Cole, K.S.; Santiago, A.E.; Mann, B.J.; Barry, E.M. Live attenuated mutants of *Francisella tularensis* protect rabbits against aerosol challenge with a virulent type A strain. *Infect. Immun.* 2014, 82, 2098–2105. [CrossRef]

23. Reed, D.S.; Smith, L.K.P.; Cole, K.S.; Santiago, A.E.; Mann, B.J.; Barry, E.M. Live attenuated mutants of *Francisella tularensis* protect rabbits against aerosol challenge with a virulent type A strain. *Infect. Immun.* 2014, 82, 2098–2105. [CrossRef]

24. Day, W.C.; Berendt, R.F. Experimental tularemia in *Macaca mulatta*: Relationship of aerosol particle size to the infectivity of airborne *Pasteurella tularensis*. *Infect. Immun.* 1972, 5, 77–82. [CrossRef]

25. Eigelsbach, H.T.; Tulis, J.J.; McGavran, M.H.; White, J.D. Live tularemia vaccine i.: Host-Parasite Relationship in Monkeys Vaccinated Intracutaneously or Aerogenically. *J. Bacteriol.* 1962, 84, 1020–1027.

26. Eigelsbach, H.T.; Tulis, J.J.; Mitten, J.Q.; Hall, W.C. Pathogenesis of tularemia in monkeys aerogenically exposed to *Francisella tularensis* 425. *Infect. Immun.* 1972, 5, 734–744. [CrossRef]

27. Tulis, J.J.; Eigelsbach, H.T.; Kerpsack, R.W. Host-parasite relationship in monkeys administered live tularenia vaccine. *Am. J. Pathol.* 1970, 58, 329–336.

28. Twenhafel, N.A.; Alves, D.A.; Purcell, B.K. Pathology of inhalational *Francisella tularensis* ssp. tularensis SCHU S4 infection in African green monkeys (*Chlorocebus aethiops*). *Vet. Pathol.* 2009, 46, 698–706. [CrossRef]

29. Holland, K.M.; Rosa, S.J.; Hazlett, K.R.O. *Francisella tularensis*—Immune Cell Activator, Suppressor, or Stealthy Evader: The Evolving View from the Petri Dish. *J. Bioterror. Biodef.* 2016, 7, 144. [CrossRef]

30. Huntley, J.F.; Conley, P.G.; Hagman, K.E.; Norgard, M.V. Characterization of *Francisella tularensis* outer membrane proteins. *J. Bacteriol.* 2007, 189, 561–574. [CrossRef]

31. Hazlett, K.R.O.; Caldon, S.D.; McArthur, D.G.; Cirillo, K.A.; Kirimanjeswara, G.S.; Magguilli, M.L.; Malik, M.; Shah, A.; Broderick, S.; Golovliov, I.; et al. Adaptation of *Francisella tularensis* to the mammalian environment is governed by cues which can be mimicked in vitro. *Infect. Immun.* 2008, 76, 4479–4488. [CrossRef]

32. Zarrella, T.M.; Singh, A.; Bitsaktsis, C.; Rahman, T.; Sahay, B.; Feustel, P.J.; Gosselin, E.J.; Sellati, T.J.; Hazlett, K.R.O. Host-Adaptation of *Francisella tularensis* Alters the Bacterium’s Surface-Carbohydrates to Hinder Effectors of Innate and Adaptive Immunity. *PLoS ONE* 2011, 6, e22335. [CrossRef]

33. Twine, S.; Shen, H.; Harris, G.; Chen, W.; Sjostedt, A.; Ryden, P.; Conlan, W. BALB/c mice, but not C57BL/6 mice immunized with a DeltaclpB mutant of *Francisella tularensis* subspecies *tularensis* are protected against respiratory challenge with wild-type bacteria: Association of protection with post-vaccination and post-challenge immune responses. *Vaccine* 2012, 30, 3634–3645. [CrossRef]

34. Sunagar, R.; Kumar, S.; Namjoshi, P.; Rosa, S.J.; Hazlett, K.R.O.; Gosselin, E.J. Evaluation of an outbred mouse model for *Francisella tularensis* vaccine development and testing. *PLoS ONE* 2018, 13, e0207587. [CrossRef]

35. Shen, H.; Harris, G.; Chen, W.; Sjostedt, A.; Ryden, P.; Conlan, W. Molecular immune responses to aerosol challenge with *Francisella tularensis* in mice inoculated with live vaccine candidates of varying efficacy. *PLoS ONE* 2010, 5, e13349. [CrossRef]

36. Ryden, P.; Twine, S.; Shen, H.; Harris, G.; Chen, W.; Sjostedt, A.; Conlan, W. Correlates of protection following vaccination of mice with gene deletion mutants of *Francisella tularensis* subspecies *tularensis* strain, SCHU S4 that elicit varying degrees of immunity to systemic and respiratory challenge with wild-type bacteria. *Mol. Immunol.* 2013, 54, 58–67. [CrossRef]

37. Griffin, A.J.; Crane, D.D.; Wehrly, T.D.; Bosio, C.M. Successful protection against tularemia in C57BL/6 mice is correlated with expansion of Francisella tularensis-specific effector T cells. *Clin. Vaccine Immunol.* 2015, 22, 119–128. [CrossRef]

38. Golovliov, I.; Lindgren, H.; Eneslatt, K.; Conlan, W.; Mosnier, A.; Henry, T.; Sjostedt, A. An In Vitro Co-culture Mouse Model Demonstrates Efficient Vaccine-Mediated Control of *Francisella tularensis* S4 and Identifies Nitric Oxide as a Predictor of Efficacy. *Front. Cell. Infect. Microbiol.* 2016, 6, 152. [CrossRef]

39. De Pascalis, R.; Mittereder, L.; Kennett, N.J.; Elkins, K.L. Activities of Murine Peripheral Blood Lymphocytes Provide Immune Correlates That Predict *Francisella tularensis* Vaccine Efficacy. *Infect. Immun.* 2016, 84, 1054–1061. [CrossRef]

40. De Pascalis, R.; Mittereder, L.; Chou, A.Y.; Kennett, N.J.; Elkins, K.L. *Francisella tularensis* Vaccines Elicit Concurrent Protective T- and B-Cell Immune Responses in BALB/cByJ Mice. *PLoS ONE* 2015, 10, e0126570. [CrossRef]

41. De Pascalis, R.; Hahn, A.; Brook, H.M.; Ryden, P.; Donart, N.; Mittereder, L.; Frey, B.; Wu, T.H.; Elkins, K.L. A panel of correlates predicts vaccine-induced protection of rats against respiratory challenge with virulent *Francisella tularensis*. *PLoS ONE* 2018, 13, e1098140. [CrossRef]

42. De Pascalis, R.; Chou, A.Y.; Bosio, C.M.; Huang, C.Y.; Follmann, D.A.; Elkins, K.L. Development of functional and molecular correlates of vaccine-induced protection for a model intracellular pathogen, *F. tularensis* LVS. *PLoS Pathog.* 2012, 8, e1002494. [CrossRef]

43. Twine, S.M.; Petit, M.D.; Fulton, K.M.; House, R.V.; Conlan, J.W. Immunoproteomics analysis of the murine antibody response to vaccination with an improved *Francisella tularensis* live vaccine strain (LVS). *PLoS ONE* 2010, 5, e100000. [CrossRef]
44. Twine, S.M.; Petit, M.D.; Shen, H.; Mykytczuk, N.C.S.; Kelly, J.F.; Conlan, J.W. Immunoproteomic analysis of the murine antibody response to successful and failed immunization with live anti-Francisella vaccines. Biochem. Biophys. Res. Commun. 2006, 346, 999–1008. [CrossRef]

45. Rahhal, R.M.; Vanden Bush, T.J.; McLendon, M.K.; Apicella, M.A.; Bishop, G.A. Differential effects of Francisella tularensis lipopolysaccharide on B lymphocytes. J. Leukoc. Biol. 2007, 82, 813–820. [CrossRef]

46. Beura, L.K.; Hamilton, S.E.; Bi, K.; Schenkel, J.M.; Odomade, O.A.; Casey, K.A.; Thompson, E.A.; Fraser, K.A.; Rosato, P.C.; Filali-Mouhim, A.; et al. Normalizing the environment recapitulates adult human immune traits in laboratory mice. Nature 2016, 532, 512–516. [CrossRef]

47. Sangesland, M.; Yousif, A.S.; Ronsard, L.; Kazer, S.W.; Zhu, A.L.; Gatter, G.J.; Hayward, M.R.; Barnes, R.M.; Quirindongo-Crespo, M.; Rohrer, D.; et al. A Single Human VH-gene Allows for a Broad-Spectrum Antibody Response Targeting Bacterial Lipopolysaccharides in the Blood. Cell Rep. 2020, 32, 108065. [CrossRef]

48. Plotkin, S.A. Updates on immunologic correlates of vaccine-induced protection. Vaccine 2020, 38, 2250–2257. [CrossRef]

49. Geier, H.; Celli, J. Phagocytic receptors dictate phagosomal escape and intracellular proliferation of Francisella tularensis. Infect. Immun. 2011, 79, 2204–2214. [CrossRef]

50. Su, J.; Yang, J.; Zhao, D.; Kawula, T.H.; Banas, J.A.; Zhang, J.R. Genome-wide identification of Francisella tularensis virulence determinants. Infect. Immun. 2007, 75, 3089–3101. [CrossRef]

51. Holland-Tummillo, K.M.; Shoudy, L.E.; Steiner, D.; Kumar, S.; Rosa, S.J.; Namjoshi, P.; Singh, A.; Sellati, T.J.; Gosselin, E.J.; Hazlett, K.R. Autotransporter-Mediated Display of Complement Receptor Ligands by Gram-Negative Bacteria Increases Antibody Responses and Limits Disease Severity. Pathogens 2020, 9, 375. [CrossRef]